Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

The purpose of this study is to assess long-term safety of SC AMG 108 in the treatment of RA

Completed

Looking for future studies?

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll.

Exclusion criteria

Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.

Treatment and study plan

AMG 108

Drug

125 mg via SC (subcutaneous) injection every 4 weeks

Primary outcomes

To assess long-term safety of AMG 108 SC in subjects with RA previously enrolled in study 20050168

Time frame: 144 Weeks

Secondary outcomes

To determine whether long-term use of AMG 108 improves function in subjects with RA

Time frame: 144 Weeks

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis

Important dates

Study start: 2006
Primary completion: 2008
Study completion: 2008
First posted: Aug 29, 2006
Registry last updated: Dec 13, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed